Explore

Trendline Trendline
Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial

Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial

Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial

Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial

Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage
Trendline Trendline
Novartis Seeks Expansion of Pluvicto for Hormone-Sensitive Prostate Cancer

Novartis Seeks Expansion of Pluvicto for Hormone-Sensitive Prostate Cancer

Novartis Seeks Expansion of Pluvicto for Hormone-Sensitive Prostate Cancer
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement
Trendline Trendline
Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates
Trendline Trendline
Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients

Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients

Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients
Trendline Trendline
Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects